Brochure | Brain Disorders | Therapeutics | Wellness

Strength Training Reduces Dementia Risk

2025-04-14 - 2025-04

A study from Brazil's State University of Campinas found that biweekly strength training significantly guards against dementia, even in individuals at high risk. Participants engaging in moderate to high-intensity weight training twice a week demonstrated improved memory and brain health, including protection of regions like the hippocampus and precuneus from atrophy.

Discovery of a New Genetic Brain Disorder

2025-04-15 - 2025-04

Researchers from Manipal Academy of Higher Education (MAHE) in India, in collaboration with U.S. universities, have identified a new genetic brain disorder linked to mutations in the EPB41L3 gene. This disorder causes seizures, developmental delays, decreased muscle tone, and defects in myelination—a process vital for nerve protection in the brain. The discovery underscores the importance of international collaboration in advancing genetic science, particularly for rare disorders.

Alzheimer's Disease Progression in Two Phases

2025-04-16 - 2025-04

A study by the U.S. National Institutes of Health suggests that Alzheimer's disease may progress in two distinct phases. The early phase affects specific brain cells before symptoms appear, while the later phase is marked by rapid deterioration. Understanding these phases could help guide the development of more effective treatments.

Maternal Diabetes and Neurodevelopmental Disorders

2025-04-17 - 2025-04

A comprehensive meta-analysis has reinforced the link between maternal diabetes during pregnancy and increased risks of neurodevelopmental disorders in children, including autism, ADHD, and intellectual disabilities. Children born to mothers with diabetes had a 28% higher likelihood of being diagnosed with such disorders. The study emphasizes the importance of medical oversight for expectant mothers with diabetes.

Surge in Brain Disorders Post-COVID-19

2025-04-19 - 2025-04

Doctors have reported a significant increase in cases of brain disorders like strokes and benign brain tumors following the COVID-19 pandemic. The incidence of brain strokes in younger populations has increased by 5-10% post-COVID-19. Other neurological conditions, such as Guillain-Barré syndrome and paralysis, have also seen a notable rise.

Leqembi Approved in the EU

2025-04-21 - 2025-04

The European Commission has approved Leqembi, developed by Eisai and Biogen, for treating early-stage Alzheimer's disease. This marks the first EU-approved medication targeting the root cause of Alzheimer's by clearing amyloid beta plaques. Approval is limited to patients with none or only one copy of the ApoE4 gene due to safety concerns.

Enhancing Brain's Immune Response

2025-04-22 - 2025-04

A Northwestern Medicine study suggests that boosting the brain's own immune cells, microglia, could offer a promising alternative to traditional treatments by enhancing the clearance of amyloid plaques.

Innovative Drug Delivery

2025-04-23 - 2025-04

Researchers at Oregon State University have developed nanoparticles capable of crossing the blood-brain barrier, potentially enabling new therapies for Alzheimer's and other brain-related disorders.

Stem Cell Therapy Shows Promise

2025-04-24 - 2025-04

Two small studies indicate that transplanting stem cells into patients' brains may offer a new treatment avenue for Parkinson's disease, showing potential in restoring dopamine-producing neurons.

Adaptive Deep Brain Stimulation (aDBS)

2025-04-25 - 2025-04

The FDA has approved aDBS, a treatment that adjusts stimulation in real-time based on brain activity, offering improved symptom management for Parkinson's patients.

High Prevalence in Northern Scotland

2025-04-28 - 2025-04

A study reveals that Northern Scotland has one of the highest rates of Huntington’s disease globally, attributed to genetic factors within local communities. This finding underscores the need for targeted healthcare resources and genetic counseling in the region.

Brain-Computer Interface Advances

2025-04-29 - 2025-04

UC Davis researchers have been recognized for developing a brain-computer interface that translates neural signals into speech, offering new hope for patients with severe motor impairments.

Non-Invasive Brain Stimulation

2025-04-30 - 2025-04

Advancements in techniques like transcranial magnetic stimulation (TMS) are opening new pathways for treating depression and other neurological disorders non-invasively.

Live Human Brain Tissue Model:

2025-05-02 - 2025-05

UK scientists have utilized living human brain tissue to replicate early stages of Alzheimer's disease. This innovative approach allows real-time observation of how toxic amyloid beta proteins disrupt synapses, potentially accelerating the search for effective treatments

Engineered Microglia Therapy:

2025-05-03 - 2025-05

Researchers at UC Irvine have developed engineered microglia capable of delivering therapeutic agents across the brain. This cell-based platform shows promise for treating Alzheimer's and other neurodegenerative diseases.

Spectris™ Device by Cognito Therapeutics

2025-05-06 - 2025-05

New data presented at AD/PD 2025 indicates that the Spectris™ device may help maintain brain structure in Alzheimer's patients, offering a novel non-pharmacological intervention.

Gantenerumab for Early-Onset Alzheimer's:

2025-05-07 - 2025-05

A study published in Lancet Neurology suggests that gantenerumab, an anti-amyloid therapy, could reduce the risk of developing symptoms in individuals genetically predisposed to early-onset Alzheimer's.

Psilocybin Shows Promise:

2025-05-08 - 2025-05

A groundbreaking study from UC San Francisco reveals that a single dose of psilocybin can significantly improve mood, motor function, and memory in Parkinson's patients, with effects lasting several weeks.

Bemdaneprocel Cell Therapy:

2025-05-09 - 2025-05

BlueRock Therapeutics has announced that bemdaneprocel, an investigational stem cell-derived therapy, has shown positive results in a Phase 1 trial. A Phase 3 trial is planned for later this year.

Alzheimer’s Disease:

2025-05-12 - 2025-05

Researchers at UC Irvine have engineered microglia—immune cells in the brain—to deliver therapeutic proteins directly to affected areas, offering a targeted approach to treating Alzheimer's and other neurological disorders.

Parkinson’s Disease:

2025-05-13 - 2025-05

The FDA has approved adaptive deep brain stimulation (aDBS) systems that adjust stimulation in real-time based on brain activity, enhancing symptom control for Parkinson’s patients.

Autism Spectrum Disorder (ASD):

2025-05-14 - 2025-05

The U.S. Department of Health and Human Services, in collaboration with NIH and CMS, has launched an initiative to analyze Medicare and Medicaid data to better understand the causes and disparities in ASD diagnosis and treatment.

Depression:

2025-05-15 - 2025-05

A study led by Monash University found that nitrous oxide, commonly known as laughing gas, may effectively treat drug-resistant depression, with 20% of participants achieving remission after four sessions.

Brain-Computer Interfaces (BCIs):

2025-05-16 - 2025-05

Precision Neuroscience has developed a minimally invasive BCI, the Layer 7 Cortical Interface, which records high-resolution brain activity without penetrating brain tissue. The device has received FDA clearance for clinical use.

Non-Invasive Brain Stimulation:

2025-05-17 - 2025-05

The FDA has granted Breakthrough Device Designation to a non-invasive brain stimulation device developed at UNC School of Medicine for treating major depressive disorder.

DGIST’s discovery of proteins that affect brain signaling opens precision treatment possibilities

2025-05-17 - 2025-05

A DGIST research team led by Professors Ko Jaewon and Um Ji Won has identified an interaction mechanism involving proteins that regulate NMDA receptor function - The discovery is expected to provide key clues for the management of mental diseases such as autism and schizophrenia

Ground-breaking discovery reveals common master switch for brain-related diseases

2025-05-20 - 2025-05

Davis Joseph discovered something that could not be found in the entire scientific history of Alzheimer's and Parkinson's research: a common master switch that can potentially cure both these and other brain-related diseases with a single method, despite the unique characteristics of each disease.

Obesity and Brain Health:

2025-05-21 - 2025-05

A study presented at the European Congress on Obesity found that abdominal obesity in adolescents is linked to structural changes in brain regions critical for memory and emotional regulation, potentially increasing the risk of cognitive impairments.

What is Normal Pressure Hydrocephalus

2025-05-26 - 2025-05

NPH or Normal Pressure Hydrocephalus is a condition in which there is fluid development inside or around the brain. This condition disrupts normal brain function. It hampers several brain-related abilities, including thinking and concentrating, memory, movement and more. While its symptoms often resemble dementia, NPH is at times reversible.

More than a mood disorder: Study reveals depression ages brain faster than normal

2025-05-27 - 2025-05

Brain ageing is related to cognitive decline, which in turn diminishes essential cognitive functions like memory, critical thinking, and more. Brain ageing is also associated with neurodegenerative conditions like dementia and Alzheimer's. The scientific community is continuously trying to identify risk factors.

Engineered Microglia for Alzheimer's:

2025-05-28 - 2025-05

Researchers at the University of California, Irvine, have developed engineered human immune cells, known as microglia, capable of delivering therapeutic agents directly to affected areas in the brain. This approach shows promise for treating Alzheimer's and other neurological disorders.

SSRIs Restore Brain Function in Alzheimer’s

2025-05-31 - 2025-05

A new study suggests that SSRIs, commonly prescribed antidepressants, may reduce biological markers of Alzheimer’s disease. In a cohort of 191 individuals, AD patients on SSRIs had lower levels of plasma phosphorylated tau-181, a key indicator of disease severity.

Niti brainstorms to prepare national brain health blueprint

2025-06-02 - 2025-06

Niti Aayog is developing a plan to improve brain health, detect cognitive disorders early, and prevent neurological diseases like Alzheimer's and Parkinson's. The initiative aims to create a service model similar to brain health clinics, focusing on early diagnosis and intervention.

'Smooth brain' disorders may share a common cause -- and potential treatment

2025-06-03 - 2025-06

Lissencephaly is a spectrum of rare, genetic disorders in which the brain fails to develop its hallmark folds. The disorders are often associated with seizures and intellectual disability and currently there are no available treatments. A new study, however, has identified a molecular mechanism that underlies some lissencephaly disorders -- and a drug that prevents and reverses lissencephaly malformations in organoids (small, three-dimensional replicas of developing brains that allow scientists to study early brain development).

Parkinson’s Disease: Morten Harket’s Diagnosis

2025-06-05 - 2025-06

Morten Harket, the 65-year-old lead singer of the band A-ha, has publicly revealed his diagnosis of Parkinson’s disease. He underwent deep brain stimulation surgeries in 2024 at the Mayo Clinic, which have improved his symptoms. Despite ongoing challenges, he continues to work on new music and remains optimistic about his creative pursuits.

World Brain Day 2025 Focuses on Lifelong Brain Health

2025-06-06 - 2025-06

The World Federation of Neurology has dedicated World Brain Day 2025 to promoting neurological well-being across all ages. The initiative emphasizes the importance of brain health from early development through older age, advocating for care, equity, and access for all.

Smooth brain disorders may share a common cause -- and potential treatment

2025-06-07 - 2025-06

Elusive Cures: Why Neuroscience Hasn’t Solved Brain Disorders—and How We Can Change That,’ an excerpt

2025-06-10 - 2025-06

Let’s take stock: As a community of brain researchers, how are we doing, In terms of the vast number of facts about the brain we have collected, we have indisputably made tremendous progress these past three decades. In that light, it’s unclear why our efforts to understand and treat certain brain and mental disorders—from Alzheimer’s disease to psychosis—remain frustrated. What exactly do we need to know, And how do we, as a community, plan to figure it out. These were the questions I was grappling with when I set out to write “Elusive Cures.”

Childhood trauma can have lasting brain consequences, cause psychiatric disorders

2025-06-11 - 2025-06

Childhood adversity may have a profound connection with lifelong vulnerability causing psychiatric disorders and other brain consequences, according to a study. The study showed that early life experiences become biologically embedded and create lasting changes in brain structure and immune function.

Healthy lifestyle habits may shield aging cells from brain disorders

2025-06-11 - 2025-06

Stroke and dementia as well as late-life depression are more common in people who have a biomarker of aging called short leukocyte telomere length, according to a study published on June 11, 2025, online in Neurology®, the medical journal of the American Academy of Neurology. The good news is that this relationship was not found in people with healthy lifestyle habits, such as eating healthy and maintaining low cholesterol and blood pressure.

Healthy lifestyle habits may shield aging cells from brain disorders

2025-06-13 - 2025-06

International Conference on Brain Disorders and Therapeutics

Brochure Form

Strength Training Reduces Dementia Risk

Discovery of a New Genetic Brain Disorder

Alzheimer's Disease Progression in Two Phases

Maternal Diabetes and Neurodevelopmental Disorders

Surge in Brain Disorders Post-COVID-19

Leqembi Approved in the EU

Enhancing Brain's Immune Response

Innovative Drug Delivery

Stem Cell Therapy Shows Promise

Adaptive Deep Brain Stimulation (aDBS)

High Prevalence in Northern Scotland

Brain-Computer Interface Advances

Non-Invasive Brain Stimulation

Live Human Brain Tissue Model:

Engineered Microglia Therapy:

Spectris™ Device by Cognito Therapeutics

Gantenerumab for Early-Onset Alzheimer's:

Psilocybin Shows Promise:

Bemdaneprocel Cell Therapy:

Alzheimer’s Disease:

Parkinson’s Disease:

Autism Spectrum Disorder (ASD):

Depression:

Brain-Computer Interfaces (BCIs):

Non-Invasive Brain Stimulation:

DGIST’s discovery of proteins that affect brain signaling opens precision treatment possibilities

Ground-breaking discovery reveals common master switch for brain-related diseases

Obesity and Brain Health:

What is Normal Pressure Hydrocephalus

More than a mood disorder: Study reveals depression ages brain faster than normal

Engineered Microglia for Alzheimer's:

SSRIs Restore Brain Function in Alzheimer’s

Niti brainstorms to prepare national brain health blueprint

'Smooth brain' disorders may share a common cause -- and potential treatment

Parkinson’s Disease: Morten Harket’s Diagnosis

World Brain Day 2025 Focuses on Lifelong Brain Health

Smooth brain disorders may share a common cause -- and potential treatment

Elusive Cures: Why Neuroscience Hasn’t Solved Brain Disorders—and How We Can Change That,’ an excerpt

Childhood trauma can have lasting brain consequences, cause psychiatric disorders

Healthy lifestyle habits may shield aging cells from brain disorders

Healthy lifestyle habits may shield aging cells from brain disorders

brain@confmeets.net

support@confmeets.net

+44 7477 467410

International Conference on
Brain Disorders and Therapeutics